URIT Medical Electronic Co.,Ltd.

URIT Medical Electronic Co., Ltd. specializes in diagnostic assay kits and laboratory instruments. Their products include immunoturbidimetric and chemiluminescent microparticle immunoassay kits for detecting biomarkers like immunoglobulin G, cardiac troponin, insulin, and cancer antigens. They also manufacture hematology analyzers (such as the URIT-5380 for automated five-part differential blood counts) and electrolyte analyzers with supporting reagents for ion-selective and pressure-based measurements. These devices are designed for clinical laboratory use to aid in diagnostic testing.

URIT Medical Electronic Co., Ltd. is headquartered in China. The company’s location is relevant for understanding its regulatory framework and manufacturing origins, though individual devices must be evaluated separately for compliance and authorization status.

URIT Medical Electronic Co., Ltd.’s devices are listed in the eudamed registry, which is the European Union’s database for medical devices. This registry provides transparency on manufacturers and their products authorized for the EU market, though it does not imply individual device approval—only that the manufacturer’s details are recorded there.

URIT’s devices fall under multiple classification categories depending on their risk level and intended use. Most of their in vitro diagnostics (IVDs) are classified as Class A, B, or C under EU regulations, with some listed under IVD Annex II List B or IVD General categories. Non-IVD devices, such as hematology analyzers, may be classified as Class I or IIa. Classification determines regulatory requirements like conformity assessment procedures, but it does not confirm authorization—only the specific device’s submission and evaluation do.

URIT’s diagnostic kits support a range of clinical assays, including immunoturbidimetric assays (e.g., for immunoglobulin G or complement C3) and chemiluminescent microparticle immunoassays (e.g., for cardiac troponin, insulin, or cancer antigens like CEA and CA19-9). These formats are used in laboratories to quantify biomarkers for conditions such as cardiovascular disease, diabetes, or cancer. The choice of assay method depends on the target analyte and the required sensitivity or specificity for clinical decision-making.